MX395148B - Método para sintetizar los análogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. - Google Patents
Método para sintetizar los análogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos.Info
- Publication number
- MX395148B MX395148B MX2018014924A MX2018014924A MX395148B MX 395148 B MX395148 B MX 395148B MX 2018014924 A MX2018014924 A MX 2018014924A MX 2018014924 A MX2018014924 A MX 2018014924A MX 395148 B MX395148 B MX 395148B
- Authority
- MX
- Mexico
- Prior art keywords
- thyroid hormone
- compounds
- pyridazinone
- polymorphonuclear leukocytes
- hormone analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a los métodos de síntesis de los compuestos de piridazinona como análogos de hormona tiroidea y sus profármacos. Los métodos preferidos de acuerdo con la divulgación permiten la preparación a gran escala de los compuestos de piridazinona que tienen pureza elevada. En algunas modalidades, los métodos preferidos de acuerdo con la divulgación también permiten la preparación de los compuestos de piridazinona en mejor rendimiento que los métodos previamente usados para preparar tales compuestos. También se divulgan las formas morfonucleares de un compuesto de piridazinona. Además se divulga un método para tratar la resistencia a la hormona tiroidea en un sujeto que tiene por lo menos una mutación de TRP.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702137P | 2012-09-17 | 2012-09-17 | |
| US201361790432P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/060177 WO2014043706A1 (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014924A MX2018014924A (es) | 2020-09-02 |
| MX395148B true MX395148B (es) | 2025-03-24 |
Family
ID=50278769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014924A MX395148B (es) | 2012-09-17 | 2013-09-17 | Método para sintetizar los análogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. |
| MX2015003418A MX364661B (es) | 2012-09-17 | 2013-09-17 | Metodo para sintetizar los analogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003418A MX364661B (es) | 2012-09-17 | 2013-09-17 | Metodo para sintetizar los analogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US9266861B2 (es) |
| EP (5) | EP4023641B1 (es) |
| JP (8) | JP6616688B2 (es) |
| KR (4) | KR20200023528A (es) |
| CN (2) | CN105008335B (es) |
| AR (1) | AR092872A1 (es) |
| AU (1) | AU2013315017C1 (es) |
| BR (2) | BR112015005891A2 (es) |
| CA (3) | CA2884481C (es) |
| DK (3) | DK2895466T3 (es) |
| ES (3) | ES2795450T3 (es) |
| FI (2) | FI4406594T3 (es) |
| HR (1) | HRP20251398T1 (es) |
| IL (7) | IL314360B2 (es) |
| IN (1) | IN2015DN03133A (es) |
| LT (2) | LT4406594T (es) |
| MX (2) | MX395148B (es) |
| MY (1) | MY170520A (es) |
| NZ (2) | NZ739645A (es) |
| PT (1) | PT4406594T (es) |
| RU (2) | RU2668960C2 (es) |
| SG (3) | SG10201705984XA (es) |
| TW (4) | TWI804870B (es) |
| WO (1) | WO2014043706A1 (es) |
| ZA (1) | ZA201501795B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4023641B1 (en) * | 2012-09-17 | 2024-05-01 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| ES2924257T3 (es) * | 2016-10-18 | 2022-10-05 | Madrigal Pharmaceuticals Inc | Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta |
| EP3725779A4 (en) * | 2018-01-23 | 2021-02-24 | Shenzhen TargetRx, Inc. | SUBSTITUTED PYRIDAZINONE COMPOUND |
| KR102531771B1 (ko) | 2018-06-12 | 2023-05-11 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 갑상선 호르몬 수용체 작용제 및 그 용도 |
| US20210292304A1 (en) * | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
| TW202019914A (zh) * | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式 |
| KR20210076932A (ko) * | 2018-10-12 | 2021-06-24 | 인벤티스바이오 컴퍼니 리미티드 | 갑상선 호르몬 수용체 작용제 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN119431265A (zh) | 2019-02-21 | 2025-02-14 | 南京瑞捷医药科技有限公司 | 一种作为甲状腺激素受体激动剂的化合物 |
| KR20220017917A (ko) * | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| CN111909137B (zh) * | 2019-05-10 | 2023-05-30 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| CN114174282A (zh) * | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| EP4017875A4 (en) | 2019-08-23 | 2023-05-03 | Terns Pharmaceuticals, Inc. | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS |
| WO2021043185A1 (en) * | 2019-09-04 | 2021-03-11 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
| AU2020346057A1 (en) | 2019-09-12 | 2022-04-21 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| CA3158379A1 (en) * | 2019-11-26 | 2021-06-03 | Hejun Lv | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| CN114787153A (zh) | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN116056709A (zh) * | 2020-08-27 | 2023-05-02 | 益方生物科技(上海)股份有限公司 | 哒嗪酮化合物 |
| AU2021341182A1 (en) * | 2020-09-10 | 2023-04-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of resmetirom, preparation method therefor, and use thereof |
| WO2022086894A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| CN114437042A (zh) * | 2020-11-03 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 酞嗪类化合物的晶型及其制备方法 |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| EP4578499A3 (en) | 2021-09-27 | 2025-09-17 | Madrigal Pharmaceuticals, Inc. | Resmetirom for reducing liver volume |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| CN116768802B (zh) * | 2023-05-25 | 2025-11-21 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗的合成方法 |
| WO2024263714A1 (en) | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| CN117263870B (zh) * | 2023-09-21 | 2026-02-06 | 江西同和药业股份有限公司 | 一种Resmetirom关键中间体III的制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025164161A1 (ja) * | 2024-01-29 | 2025-08-07 | シオノギファーマ株式会社 | カンナビジオールの溶媒和物及びカンナビジオールの精製方法 |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025191457A1 (en) * | 2024-03-13 | 2025-09-18 | Morepen Laboratories Limited | Process for the preparation of pyridazinone derivative |
| CN119019375A (zh) * | 2024-08-14 | 2024-11-26 | 奥锐特药业(天津)有限公司 | 一种瑞司美替罗新晶型及其制备方法 |
| CN119306670A (zh) * | 2024-10-12 | 2025-01-14 | 北京海美桐医药科技有限公司 | 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) * | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| DE602004021901D1 (de) * | 2003-01-28 | 2009-08-20 | Academisch Ziekenhuis Leiden | Aus ll-37 abgeleiteten peptidinhibitoren von toxinen |
| EP1608629A1 (en) | 2003-03-24 | 2005-12-28 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| US20080152700A1 (en) * | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
| CA2614529C (en) * | 2005-07-21 | 2011-06-28 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
| JP5243537B2 (ja) | 2007-06-06 | 2013-07-24 | トレント ファーマシューティカルズ リミテッド | 新規化合物 |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| EP4023641B1 (en) | 2012-09-17 | 2024-05-01 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| CA2939076A1 (en) | 2014-02-14 | 2015-08-20 | Cempra Pharmaceuticals, Inc. | Compositions and methods for treating diabetes and liver diseases |
| ES2924257T3 (es) | 2016-10-18 | 2022-10-05 | Madrigal Pharmaceuticals Inc | Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta |
| KR102531771B1 (ko) | 2018-06-12 | 2023-05-11 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 갑상선 호르몬 수용체 작용제 및 그 용도 |
| TW202019914A (zh) | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式 |
| KR20210076932A (ko) | 2018-10-12 | 2021-06-24 | 인벤티스바이오 컴퍼니 리미티드 | 갑상선 호르몬 수용체 작용제 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
-
2013
- 2013-09-17 EP EP21209827.1A patent/EP4023641B1/en active Active
- 2013-09-17 MX MX2018014924A patent/MX395148B/es unknown
- 2013-09-17 CN CN201380059943.5A patent/CN105008335B/zh active Active
- 2013-09-17 TW TW110117935A patent/TWI804870B/zh active
- 2013-09-17 SG SG10201705984XA patent/SG10201705984XA/en unknown
- 2013-09-17 KR KR1020207005528A patent/KR20200023528A/ko not_active Ceased
- 2013-09-17 HR HRP20251398TT patent/HRP20251398T1/hr unknown
- 2013-09-17 KR KR1020187034908A patent/KR102138750B1/ko active Active
- 2013-09-17 ES ES13837402T patent/ES2795450T3/es active Active
- 2013-09-17 AR ARP130103332A patent/AR092872A1/es active IP Right Grant
- 2013-09-17 RU RU2015114327A patent/RU2668960C2/ru active
- 2013-09-17 AU AU2013315017A patent/AU2013315017C1/en active Active
- 2013-09-17 CA CA2884481A patent/CA2884481C/en active Active
- 2013-09-17 IL IL314360A patent/IL314360B2/en unknown
- 2013-09-17 DK DK13837402.0T patent/DK2895466T3/da active
- 2013-09-17 IL IL320269A patent/IL320269A/en unknown
- 2013-09-17 EP EP24173563.8A patent/EP4406594B1/en active Active
- 2013-09-17 NZ NZ73964513A patent/NZ739645A/en unknown
- 2013-09-17 PT PT241735638T patent/PT4406594T/pt unknown
- 2013-09-17 FI FIEP24173563.8T patent/FI4406594T3/fi active
- 2013-09-17 MX MX2015003418A patent/MX364661B/es active IP Right Grant
- 2013-09-17 BR BR112015005891A patent/BR112015005891A2/pt not_active Application Discontinuation
- 2013-09-17 CA CA3090070A patent/CA3090070C/en active Active
- 2013-09-17 CN CN201810077707.0A patent/CN108101851A/zh active Pending
- 2013-09-17 WO PCT/US2013/060177 patent/WO2014043706A1/en not_active Ceased
- 2013-09-17 IL IL288133A patent/IL288133B2/en unknown
- 2013-09-17 LT LTEP24173563.8T patent/LT4406594T/lt unknown
- 2013-09-17 CA CA3111317A patent/CA3111317C/en active Active
- 2013-09-17 KR KR1020217019940A patent/KR102363776B1/ko active Active
- 2013-09-17 DK DK24173563.8T patent/DK4406594T3/da active
- 2013-09-17 JP JP2015532148A patent/JP6616688B2/ja active Active
- 2013-09-17 BR BR122021024202-0A patent/BR122021024202B1/pt active IP Right Grant
- 2013-09-17 TW TW107137798A patent/TWI681957B/zh active
- 2013-09-17 EP EP20157696.4A patent/EP3689853B1/en active Active
- 2013-09-17 MY MYPI2015000591A patent/MY170520A/en unknown
- 2013-09-17 TW TW108132827A patent/TWI755628B/zh active
- 2013-09-17 IN IN3133DEN2015 patent/IN2015DN03133A/en unknown
- 2013-09-17 TW TW102133687A patent/TWI652260B/zh active
- 2013-09-17 ES ES24173563T patent/ES3053122T3/es active Active
- 2013-09-17 EP EP13837402.0A patent/EP2895466B1/en active Active
- 2013-09-17 KR KR1020157009807A patent/KR101966490B1/ko active Active
- 2013-09-17 SG SG10202006058QA patent/SG10202006058QA/en unknown
- 2013-09-17 RU RU2018128393A patent/RU2018128393A/ru unknown
- 2013-09-17 DK DK20157696.4T patent/DK3689853T3/da active
- 2013-09-17 NZ NZ705827A patent/NZ705827A/en unknown
- 2013-09-17 EP EP25200792.7A patent/EP4691557A3/en active Pending
- 2013-09-17 SG SG11201501907YA patent/SG11201501907YA/en unknown
- 2013-09-17 ES ES20157696T patent/ES2907926T3/es active Active
-
2015
- 2015-03-09 IL IL237628A patent/IL237628B/en active IP Right Grant
- 2015-03-16 ZA ZA2015/01795A patent/ZA201501795B/en unknown
- 2015-03-17 US US14/660,720 patent/US9266861B2/en active Active
-
2016
- 2016-02-17 US US15/046,213 patent/US9968612B2/en active Active
-
2017
- 2017-12-26 JP JP2017249107A patent/JP6532931B2/ja active Active
-
2018
- 2018-04-10 US US15/949,389 patent/US10376517B2/en active Active
- 2018-05-27 IL IL259610A patent/IL259610B/en active IP Right Grant
- 2018-11-20 JP JP2018217045A patent/JP6765408B2/ja active Active
-
2019
- 2019-02-25 IL IL265030A patent/IL265030B/en active IP Right Grant
- 2019-07-01 US US16/458,546 patent/US10894050B2/en active Active
- 2019-08-27 JP JP2019154299A patent/JP6899413B2/ja active Active
-
2020
- 2020-02-10 JP JP2020020343A patent/JP7038745B2/ja active Active
- 2020-06-15 IL IL275393A patent/IL275393B/en unknown
- 2020-12-11 US US17/118,706 patent/US11564926B2/en active Active
-
2022
- 2022-03-07 JP JP2022034154A patent/JP7436542B2/ja active Active
- 2022-12-15 US US18/066,677 patent/US20230210856A1/en not_active Abandoned
-
2023
- 2023-12-22 US US18/393,813 patent/US11986481B2/en active Active
- 2023-12-22 US US18/393,818 patent/US20240148742A1/en not_active Abandoned
-
2024
- 2024-02-07 JP JP2024016915A patent/JP2024056793A/ja active Pending
-
2025
- 2025-09-03 JP JP2025145966A patent/JP2025179154A/ja active Pending
-
2026
- 2026-02-20 LT LTPA2026507C patent/LTPA2026507I1/lt unknown
- 2026-03-03 FI FIC20265007C patent/FIC20265007I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX395148B (es) | Método para sintetizar los análogos de hormona tiroidea y leucocitos polimorfonucleares de los mismos. | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| MD20180040A2 (ro) | Inhibitori ai virusului hepatic C | |
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| MX2015011723A (es) | Proceso para la preparacion de una sal de sodio de (2s, 5r) -2-carboxamido-7-oxo-6-sulfooxi-1,6-diaza-biciclo[3.2.1]-octano. | |
| IN2014MN01521A (es) | ||
| MX362752B (es) | Formas mórficas de ésteres de hexadeciloxipropil-fosfonato. | |
| WO2012031045A3 (en) | Phosphonate ester derivatives and methods of synthesis thereof | |
| EA201391056A1 (ru) | Гетероарильные соединения в качестве лигандов 5-htрецептора | |
| FR2983198B1 (fr) | Procede de preparation de derives de 5-amino-benzoyl-benzofurane | |
| MY178759A (en) | Method for preparing trichlorosilane | |
| TN2012000620A1 (fr) | Procede de preparation du sel de l-arginine du perindopril | |
| MX2017001459A (es) | Sintesis de fosforamidatos. | |
| IN2015MN00013A (es) | ||
| EA201690755A1 (ru) | Солевые и кристаллические формы ингибитора plk-4 | |
| BR112012031086A2 (pt) | intermediários de agomelatina e método de preparação dos mesmos | |
| EA201590116A1 (ru) | Способ получения замещенных триазолопиридинов | |
| TN2014000329A1 (en) | Method for preparing compound by novel michael addition reaction using water or various acids as additive | |
| MX338556B (es) | Metodos para aislar acidos 4-cloro-2-fluoro-3-fenilboronicos sustituidos. | |
| CA2928305C (en) | A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof | |
| MX2015003237A (es) | Metodos para producir molindona y sus sales. | |
| Ohta et al. | Development for an Improved Process of Selective Prostaglandin Receptor Agonist ONO-4819 | |
| IN2012DE00267A (es) | ||
| IN2013MU03467A (es) | ||
| IN2013DE00241A (es) |